Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
A Phase II Study of BKM 120 for Patients With Recurrent Glioblastoma and Activated PI3K Pathway
Sponsor: Brigham and Women's Hospital
Listed as NCT01339052, this PHASE2 trial focuses on Glioblastoma and remains completed. Sponsored by Brigham and Women's Hospital, it has been updated 10 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Brigham and Women's Hospital
- M.D. Anderson Cancer Center
- Massachusetts General Hospital
- Memorial Sloan Kettering Cancer Center
- Novartis Pharmaceuticals
- Patrick Y. Wen, MD
- University of California, Los Angeles
- University of California, San Francisco
- University of Utah
For direct contact, visit the study record on ClinicalTrials.gov .